Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 9/20 | 0.40 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16563732 | 0.88 | PDE2A (0.42) | ALDH1A1HPGDPDE2AMMP12MMP13 | |
| SCHEMBL18493015 | 0.82 | FAAH (0.40) | ALDH1A1HPGD | |
| SCHEMBL16830012 | 0.81 | OPRK1 (0.44) | — | |
| SCHEMBL14831389 | 0.80 | PKM (0.48) | — | |
| SCHEMBL16563805 | 0.79 | EPHX1 (0.48) | ALDH1A1HPGDPDE2AMMP12MMP13 | |
| SCHEMBL16563426 | 0.77 | POLB (0.46) | ALDH1A1PDE2AMMP12MMP13EPHX2 | |
| SCHEMBL16563695 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HPGDPDE2AMMP12MMP13 | |
| SCHEMBL16633285 | 0.75 | ALDH1A1 (0.36) | ALDH1A1HPGDPDE2AEPHX2 | |
| SCHEMBL16563741 | 0.74 | PDE2A (0.46) | ALDH1A1PDE2AEPHX2POLB | |
| SCHEMBL16563731 | 0.74 | FFAR4 (0.43) | PDE2AMMP12MMP13EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | ALDH1A1 492/4885HPGD 377/4885PDE2A 1/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | ALDH1A1 492/4885HPGD 377/4885PDE2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.